The elevated risk that cancer patients face during the COVID-19 pandemic poses many challenges. Some of these include providing ongoing cancer treatments especially if patients are undergoing curative therapy, enrolling patients into experimental drug trials, continuing close cardiotoxicity surveillance, and providing treatments to patients who have an optimal window of adequate functional status [47, 48]. Given concerns for hospital-acquired COVID-19 infections, this additional risk factor can impact continuation of therapy or initiation of regimens for aggressive malignancy that require hospitalization for closer monitoring [43, 47, 48]. Moreover, patients that may rely on drugs or stem cell donations for treatment may necessitate access to unique global sources and are rendered at a disadvantage due to travel restrictions and quarantine policies [49]. In response to these climactic changes, The National Comprehensive Cancer Network and National Cancer Institute have provided guidance to providers on providing care to oncology patients, resource allocation, and managing drug trials [50].